Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study.

MLA

Jeong, Hyehyun, et al. “Liposomal Irinotecan, Oxaliplatin, and S-1 as First-Line Therapy for Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma (NASOX): A Multicenter Phase I/IIa Study.” European Journal of Cancer, vol. 208, Sept. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejca.2024.114194.

APA

Jeong, H., Kim, B. J., Lee, C., Park, I., Zang, D. Y., Choi, H. J., Lee, S. S., Park, D. H., Song, T. J., Oh, D., Moon, S.-H., Kim, K., Wainberg, Z., Ryoo, B.-Y., & Yoo, C. (2024). Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study. European Journal of Cancer, 208, N.PAG. https://doi.org/10.1016/j.ejca.2024.114194

Chicago

Jeong, Hyehyun, Bum Jun Kim, Choong-kun Lee, Inkeun Park, Dae Young Zang, Hye Jin Choi, Sang Soo Lee, et al. 2024. “Liposomal Irinotecan, Oxaliplatin, and S-1 as First-Line Therapy for Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma (NASOX): A Multicenter Phase I/IIa Study.” European Journal of Cancer 208 (September): N.PAG. doi:10.1016/j.ejca.2024.114194.